Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Niacin Clear all
Completed Phase 2 Interventional Results available

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

NCT00855218
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 28, 2026, 4:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Niaspan on Cholesterol in Men

NCT00765284
View directory record Official record
Conditions
HDL Cholesterol
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Alii Supplement Study

NCT07271316
View directory record Official record
Conditions
Nutrient Deficiency, Happiness, Digestive Health, Vulnerability to Disease, Mood Swings, Energy
Interventions
Alii Supplement
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Results available

A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

NCT01469065
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-04991532, PF-0499132, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 28, 2026, 4:50 PM EDT
Recruiting Phase 2Phase 3 Interventional

Psilocybin Therapy in Advanced Cancer

NCT05398484
View directory record Official record
Conditions
Advanced Cancer
Interventions
Psilocybin 25 mgs, Niacin 100mg, Psychotherapy
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

NCT02942888
View directory record Official record
Conditions
Mild Cognitive Impairment, NAD
Interventions
Nicotinamide riboside, Sugar Pill
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Early Phase 1 Interventional

Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury

NCT02701127
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Oral niacinamide, 1 gram daily, Oral niacinamide, 3 gram daily, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 28, 2026, 4:50 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

NCT00300885
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

Niacin, N-3 Fatty Acids and Insulin Resistance

NCT00286234
View directory record Official record
Conditions
Metabolic Syndrome, Hypertriglyceridemia
Interventions
omega-3 acid ethyl esters, extended release niacin, placebo, combined treatment
Drug
Lead sponsor
University of South Dakota
Other
Eligibility
40 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 2 Interventional

Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

NCT02558595
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Niacinamide, Placebo
Dietary Supplement · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 1Phase 2 Interventional

The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients

NCT00508885
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Niacinamide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2007 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

NCT04809974
View directory record Official record
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes

NCT02721537
View directory record Official record
Conditions
Concussion, Mild
Interventions
Nicotinamide Riboside, Matching placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)

NCT01152073
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, Second Formulation, Third Formulation
Dietary Supplement
Lead sponsor
Healthy Drink Discoveries, Inc.
Other
Eligibility
20 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 28, 2026, 4:50 PM EDT
Terminated Phase 2 Interventional Results available

Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery

NCT00796887
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Extended-Release Niacin, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 2 Interventional

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

NCT00079612
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 1 Interventional

Psilocybin-assisted Therapy for Phantom Limb Pain

NCT05224336
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Psilocybin, Placebo Niacin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin)

NCT03797469
View directory record Official record
Conditions
Visual Field Defect, Peripheral, Glaucoma, Open-Angle
Interventions
Vitamin B3, Pyruvate, Placebo
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 28, 2026, 4:50 PM EDT
Recruiting Not applicable Interventional

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

NCT06044935
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Standard Diet, Ketogenic Diet, Placebo, Nicotinamide Riboside
Other · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 4:50 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
Ralitza Gavrilova
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 28, 2026, 4:50 PM EDT
Recruiting Phase 2 Interventional

Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery

NCT07013591
View directory record Official record
Conditions
Cardiac Surgery
Interventions
MIB-626, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

Niacin and Endothelial Function in Early CKD

NCT00852969
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Niacin, Active Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

NCT00302744
View directory record Official record
Conditions
Anxiety
Interventions
Psilocybin (drug), Niacin, MRI
Drug · Other · Diagnostic Test
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 28, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

NCT01336738
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Placebo, 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Sep 28, 2026, 4:50 PM EDT